ETFs positioned on AstraZeneca PLC

Name YTD change Weight AuM
+18.12% - 334,922 M€
+16.21% - 2,210 M€
+5.89% - 1,193 M€
+20.56% - 1,646 M€
-1.98%4.85% 5 M€
+26.18%4.05% 81 M€
+7.42%3.39% 94 M€
+12.24%1.83% 331 M€
+19.27%1.5% 210 M€
+9.35%1.29% 1,882 M€
+17.46%1.15% 19 M€
+8.07%1.12% 6,576 M€
+22.07%1.06% 122 M€
+19.18%1% 13 M€
+9.01%0.62% 8 M€
+6.64%0.54% 361 M€
+8.16%0.42% 8,285 M€
+7.43%0.31% 5,369 M€
+14.66%0.3% 630 M€
+24.34%0.3% 2,914 M€
-6.15%0.3% 15 M€
+22.64%0.3% 38 M€
+19.80%0.3% 100 M€
+14.60%0.3% 16 M€
+7.51%0.29% 40 M€
+16.93%0.29% 115 M€
+20.17%0.29% 138 M€
+0.48%0.28% 13,961 M€
+22.96%0.27% 6,226 M€
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100